Drug intelligence / Profile preview

miR-125 mimic

Development stage
Preclinical
Lead developer
Shanghai GenePharma
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Subcutaneous
01

Overview

miR-125 mimic is a synthetic, double-stranded RNA oligonucleotide designed to simulate the biological activity of endogenous microRNA-125 (miR-125). In various cancers, including cervical cancer, miR-125 functions as a tumor suppressor but is frequently downregulated. The mimic acts by binding to the 3'-untranslated region (3'-UTR) of specific target messenger RNAs, most notably Vascular Endothelial Growth Factor (VEGF), leading to translational repression or mRNA degradation. This downregulation of VEGF inhibits the activation of the PI3K/AKT signaling pathway, which is critical for cell proliferation, survival, and metastasis. Preclinical studies have demonstrated that miR-125 mimics can significantly reduce tumor growth, migration, and invasion in vitro and in vivo.

Other names
microRNA-125 mimicmicroRNA125 mimicmicroRNA 125 mimichsa-miR-125 mimichsa-miR125 mimichsa-miR 125 mimicmiR-125a mimicmiR125a mimicmiR 125a mimicmiR-125b mimicmiR125b mimicmiR 125b mimic
02

Targets

Beyond the preview

Go deeper on miR-125 mimic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-125 mimic.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call